Finzati - Logo
CRMD logo

CorMedix Inc.

CRMD • Biotechnology
$8.43
▼ -0.04 (-0.47%)
Current price
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$780.14M
Growth
—
Cash Flow
1/5
Trend
Volatile
Evidence
Stable or improving margins · 52.3%Positive revenue growth · 440.3%Positive free cash flow · 2.4Reasonable earnings multiple · 5.14Manageable debt level · 0.37
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:11 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$8.43
Change-0.47%
Shares Out92.54M
Market Cap$780.14M
Enterprise Value$668.60M
52W Range6.13 - 14.96
Beta1.50
P/E4.17
P/S1.69
P/B1.69
P/FCF3.08
EV/Sales1.45

Investment DNA

How strong this company looks for long-term investors

85
out of 100
Business Quality
Margins, moat, returns
90/100
Financial Strength
Debt, cash, stability
94/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
90/100
Why this score▼
Stable or improving margins · 52.3%Positive revenue growth · 440.3%Positive free cash flow · 2.4Reasonable earnings multiple · 5.14Manageable debt level · 0.37Healthy liquidity · 2.11

Analyst view

Analyst sentiment and price target

CRMD
Analyst sentiment
Based on 8 analyst votes · 2026-09-05
100/100
Bullish
Bullish
8
Hold
0
Bearish
0
Price Target
2026-08-14
Low
$13.00
Mean
$13.50
Median
$13.50
High
$14.00

Company Overview

IPO: 5/13/2010
Industry: Biotechnology
P/B i: 1.69
Debt / Equity i: 0.37
Operating Margin: 48.17%
Net Margin: 52.31%
ROE i: -
ROIC: -

Financial Health

Score19 / 20
Debt / Equity: 0.37
Current Ratio: 2.11
Quick Ratio: 1.94
Status: Strong

Insider Transactions

Recent executive and insider activity

Todisco Joseph
Transaction: 02/04/2026
BUY
Change
+77,156
Price
Not reported
Filing
02/06/2026
Type
BUY
Hurlburt Elizabeth
Transaction: 02/04/2026
BUY
Change
+36,006
Price
Not reported
Filing
02/06/2026
Type
BUY
Zelnick Kaufman Beth
Transaction: 02/04/2026
BUY
Change
+36,006
Price
Not reported
Filing
02/06/2026
Type
BUY